Original Source(s)
Related Content
Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?
A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.
July 8, 2026
-
3 min
ASE Plenary: Progress, Priorities, and What’s Next
Efforts to align, sustain, and engage drove a year of growth for ASE.
June 26, 2026
-
4 min